Matt Phipps
Stock Analyst at William Blair
(1.47)
# 3,578
Out of 5,136 analysts
25
Total ratings
41.18%
Success rate
-6.33%
Average return
Main Sectors:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Initiates: Outperform | n/a | $6.04 | - | 1 | Jan 5, 2026 | |
| DVAX Dynavax Technologies | Downgrades: Market Perform | n/a | $15.60 | - | 1 | Dec 24, 2025 | |
| EVMN Evommune | Initiates: Outperform | n/a | $21.25 | - | 1 | Dec 1, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $6.17 | - | 3 | Oct 17, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | n/a | $3.96 | - | 1 | Oct 16, 2025 | |
| INSM Insmed | Initiates: Outperform | n/a | $163.46 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $11.72 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $1.62 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $1.57 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $14.45 | - | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $35.34 | - | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.53 | - | 1 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $32.30 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $18.27 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.87 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $57.02 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.12 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.55 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $169.31 | - | 2 | Jun 8, 2021 |
Compass Therapeutics
Jan 5, 2026
Initiates: Outperform
Price Target: n/a
Current: $6.04
Upside: -
Dynavax Technologies
Dec 24, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $15.60
Upside: -
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: n/a
Current: $21.25
Upside: -
Kezar Life Sciences
Oct 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.17
Upside: -
Climb Bio
Oct 16, 2025
Initiates: Outperform
Price Target: n/a
Current: $3.96
Upside: -
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $163.46
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $11.72
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.62
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.57
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $14.45
Upside: -
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $35.34
Upside: -
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $19.53
Upside: -
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $32.30
Upside: -
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $18.27
Upside: -
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $10.87
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $57.02
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.12
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.55
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $169.31
Upside: -